Dr. Kahl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5225 Mid America Plz
Saint Louis, MO 63129Phone+1 314-747-7222Fax+1 314-286-1021- Is this information wrong?
Summary
- Dr. Brad Kahl is a hematologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from Tufts University School of Medicine and has been in practice 23 years. He specializes in the treatment of lymphoma and CLL and is experienced in hematologic oncology and benign hematology.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1998 - 2000- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1994 - 1998
Tufts University School of MedicineClass of 1994
Certifications & Licensure
MO State Medical License 2015 - 2025
IL State Medical License 2020 - 2023
WI State Medical License 1995 - 2015- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 23
- Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
- Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis o...Brown, J., Ghia, P., Jurczak, W., Kahl, B., Lamanna, N., Robak, T., Shadman, M., Tam, C., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, ...> ;Haematologica. 2024 Feb 29
- 2 citationsSOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma.Dilan Patel, Brad Kahl> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
- 2 citationsEBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.Agrawal, P., David, K., Chen, Z., Sundaram, S., Kim, S., Vaca, R., Lin, Y., Singer, S., Malecek, M., Carter, J., Zayac, A., Kim, M., Reddy, N., Ney, D., Habib, A., Str...> ;Leukemia & Lymphoma. 2023 May 1
- Join now to see all
Journal Articles
- Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas into Effective New TherapiesDaniel J Landsburg, Brad S Kahl, Clinical Lymphoma, Myeloma, & Leukemia
- Ibrutinib for the Treatment of relapsed/refractory Mantle Cell Lymphoma: Extended 3.5-year Follow-up from a Pooled AnalysisBrad Kahl, Andre Goy, Haematologica
- CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PETDavid J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Abstracts/Posters
- Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell LymphomaBrad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes Following Early Relapse in Patients with Mantle Cell LymphomaBrad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect PatientsApril 28th, 2023- Autologous Stem Cell Transplant for Mantle Cell Lymphoma and the Transition Toward the Use of BTK InhibitorsJanuary 31st, 2023
- FDA Approves First-in-Class Drug for Follicular LymphomaDecember 23rd, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Barnes-Jewish HospitalSaint Louis, Missouri
Siteman Cancer CenterSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
